Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Timothy J. Turner et al.|The Lancet Neurology|2021Cited by 192
Switching from natalizumab to fingolimodLudwig Kappos, Athanasios P. Kyritsis, Ernst‐Wilhelm Radue et al.|Neurology|2015Cited by 116
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104